FOVISTA: Assaig clínic per pacients amb DMAE neovascular subfoveal 19/03/2014

Descripció

A phase 3 Randomized, doubled masked, controlled trial to establish the safety and efficacy of intravitreous administration of FOVISTA (anti-PDGF-b pegylated aptamer) administered in combination with Lucentis compared to Lucentis Monotherpahy in subjects with subfoveal neovascular age-related macular degeneration

Objectius

The objectives of the study are to evaluate the safety and efficacy of FOVISTA in combination with ranibizumab (Lucentis) as compared to ranibizumab monotherapy in patients with neovascular age-related macular degeneration who have not received previous treatment.

Més informació sobre els assaigs clínics en aquest vídeo.

Si vols participar en un assaig clínic consulta’ns al +34 93 595 01 55 i avaluarem si ets elegible.

Autor

Dr. Jordi Monés, M.D., Ph.D.
Número de Col·legiat COMB: 22.838
Director
Doctor en Medicina i Cirurgia
Especialista en Oftalmologia
Especialista en Retina, Màcula i Vitri